ADAMTS13: What it does, how it works, and why it's important

Transfusion

Volumn 49, Issue 2, 2009, Pages 196-198

  George, James N ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD36 ANTIGEN; CORTICOSTEROID; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CELL SURFACE; DISEASE SEVERITY; EDITORIAL; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BINDING; ENZYME DEFICIENCY; HUMAN; MEDICAL DECISION MAKING; PLASMA TRANSFUSION; PLASMAPHERESIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; THROMBOCYTE MEMBRANE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM; VON WILLEBRAND FACTOR CLEAVING PROTEINASE DEFICIENCY;

ADAM PROTEINS; BLOOD PROTEINS; DISINTEGRINS; HUMANS; METALLOPROTEASES; PROTEIN STRUCTURE, TERTIARY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSPONDINS; VON WILLEBRAND FACTOR;

EID: 58849136365     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.02060.x     Document Type: Editorial

References (25)

1. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006 203 : 767 76.
2. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339 : 1578 84.
3. Tsai HM, Lian EC. Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 : 1585 94.
4. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto T, Mori T, Wanaka A, Fukui H, Fujimura Y. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005 106 : 922 4.
5. Shang D, Zheng XW, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their associatioin with lipid rafts. Blood 2006 106 : 2207 15.
6. Chauhan AK, Walsh MT, Zhu G, Ginsburg D, Wagner DD, Motto DG. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008 111 : 3452 7.
7. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 2008 112 : 1713 9.
8. 3 integrin. J Thromb Haemost 2007 5 : 583 9.
9. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008 111 : 651 7.
10. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, López JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002 100 : 4033 9.
11. Davis AK, Makar RS, Stowell CP, Kuter DJ, Dzik WH. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion DOI: 10.1111/j.1537-2995.2008.01978.x
12. Pfueller SL, David R, Firkin BG, Bilston RA, Cortizo WF, Raines G. Platelet aggregating IgG antibody to platelet surface glycoproteins associated with thrombosis and thrombocytopenia. Br J Haematol 1990 74 : 336 41.
13. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994 88 : 816 25.
14. Schultz DR, Arnold PI, Jy W, Valant PA, Gruber J. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 1998 103 : 849 57.
15. Wright JF, Wang H, Hornstein A, Hogarth M, Mody M, Garvey MB, Blanchette V, Rock G, Freedman J. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1999 107 : 546 55.
16. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982 307 : 1432 5.
17. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966 45 : 139 59.
18. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991 325 : 393 7.
19. George JN, Terrell DR, Swisher KK, Vesely SK. Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry. J Clin Apher 2008 23 : 129 37.
20. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006 107 : 528 34.
21. Nguyen TC, Liu A, Liu L, Ball C, Choi H, May WS, Aboulfatova K, Bergeron AL, Dong JF. Acquired ADAMTS13 deficiency in pediatric patients with severe sepsis. Haematologia 2007 92 : 121 4.
22. Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Morioka C, Yoshiji H, Tsujimoto T, Kurumatani N, Fukui H. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008 99 : 1019 29.
23. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS 13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologia 2008 93 : 232 9.
24. Kiss JE. Randomized clinical trials in thrombotic thrombocytopenic purpura: where do we go from here? Transfusion 2006 46 : 1659 62.
25. Johnson KK, Terrell DR, Lammle B, Kremer Hovinga JA, George JN, Vesely SK. Predicting risk for relapse in patients who have recovered from thrombotic thrombocytopenic purpura. Blood 2006 108 : 31a.